LENZ Therapeutics, Inc. SEC filings LENZ
LENZ Therapeutics, Inc. has 359 filings in SEC EDGAR's recent list, going back to Mar 19, 2021. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations, exit or restructuring costs, officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 14, 2025 | — |
| EFFECT | Filing | Apr 14, 2025 | — |
| CORRESP | Letter to the SEC | Apr 10, 2025 | — |
| CORRESP | Letter to the SEC | Apr 10, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 10, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 10, 2025 | — |
| EFFECT | Filing | Apr 8, 2025 | — |
| EFFECT | Filing | Apr 8, 2025 | — |
| EFFECT | Filing | Sep 19, 2024 | — |
| CORRESP | Letter to the SEC | Sep 17, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 13, 2024 | — |
| EFFECT | Filing | Apr 10, 2024 | — |
| CORRESP | Letter to the SEC | Apr 8, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2024 | — |
| 425 | Filing | Mar 8, 2024 | — |
| 425 | Filing | Mar 5, 2024 | — |
| SEC STAFF LETTER | Filing | Feb 13, 2024 | — |
| EFFECT | Filing | Feb 13, 2024 | — |
| CORRESP | Letter to the SEC | Feb 9, 2024 | — |
| CORRESP | Letter to the SEC | Feb 9, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 9, 2024 | — |
| CORRESP | Letter to the SEC | Feb 5, 2024 | — |
| SEC STAFF LETTER | Filing | Feb 1, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 1, 2024 | — |
| CORRESP | Letter to the SEC | Jan 17, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 5, 2024 | — |
| 425 | Filing | Dec 26, 2023 | — |
| 425 | Filing | Nov 15, 2023 | — |
| 425 | Filing | Nov 15, 2023 | — |
| EFFECT | Filing | Jul 28, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 26, 2022 | — |
| CORRESP | Letter to the SEC | Jul 26, 2022 | — |
| EFFECT | Filing | Jun 24, 2021 | — |
| CERT | Filing | Jun 24, 2021 | — |
| SEC STAFF LETTER | Filing | Jun 24, 2021 | — |
| 8-A12B | Filing | Jun 22, 2021 | — |
| CORRESP | Letter to the SEC | Jun 22, 2021 | — |
| CORRESP | Letter to the SEC | Jun 22, 2021 | — |
| CORRESP | Letter to the SEC | Jun 22, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 22, 2021 | — |
| SEC STAFF LETTER | Filing | Jun 15, 2021 | — |
| CORRESP | Letter to the SEC | Jun 11, 2021 | — |
| CORRESP | Letter to the SEC | Jun 10, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 7, 2021 | — |
| DRSLTR | Filing | May 21, 2021 | — |
| DRS/A | Filing | May 21, 2021 | — |
| UPLOAD | Letter from the SEC | May 14, 2021 | — |
| DRS | Filing | Apr 16, 2021 | — |
| D | Filing | Mar 19, 2021 | — |
Showing 49 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LENZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Solana Beach, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1815776
- Former names
- Graphite Bio, Inc. (until Mar 19, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.